TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort. Meeting Abstract

Industry Collaboration

cited authors

  • Konstantinopoulos, Panagiotis A.; Waggoner, Steven E.; Vidal, Gregory A.; Mita, Monica M.; Fleming, Gini F.; Holloway, Robert W.; Van Le, Linda; Sachdev, Jasgit C.; Chapman-Davis, Eloise; Colon-Otero, Gerardo; Penson, Richard T.; Matulonis, Ursula A.; Kim, Young B.; Moore, Kathleen N.; Swisher, Elizabeth M.; Dezube, Bruce Jeffrey; Wang, Jing Y.; Buerstatte, Nathan; Arora, Sujata; Munster, Pamela N.

authors

Publication Date

  • May 20, 2018

webpage

published in

category

volume

  • 36

issue

  • 15